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Background: The goal of this study was to assess the effect of a controlled adverse environ-
ment (CAE) challenge on subjects with both allergic conjunctivitis and dry eye.
Methods: Thirty-three subjects were screened and 17 completed this institutional review 
board-approved study. Subjects underwent baseline ocular assessments and conjunctival allergen 
challenge (CAC) on days 0 and 3. Those who met the ocular redness and itching criteria were 
randomized to receive either the controlled adverse environment (CAE) challenge (group A, 
n = 9) or no challenge (group B, n = 8) at day 6. Thirty minutes after CAE/no-CAE, subjects 
were challenged with allergen and their signs and symptoms graded. Exploratory confocal 
microscopy was carried out in a subset of subjects at hourly intervals for 5 hours post-CAC 
on days 3 and 6.
Results: Seven minutes post-CAC, subjects exposed to the CAE had significantly greater 
itching (difference between groups, 0.55 ± 0.25, P = 0.028), conjunctival redness (0.59 ± 0.19, 
P = 0.002), episcleral redness (0.56 ± 0.19, P = 0.003) and mean overall redness (mean of 
conjunctival, episcleral, and ciliary redness, 0.59 ± 0.14, P , 0.001). The mean score at 7, 15, 
and 20 minutes post-CAC for conjunctival redness (0.43 ± 0.17, P = 0.012), episcleral redness 
(0.49 ± 0.15, P = 0.001), mean overall redness in all regions (0.43 ± 0.15, P = 0.005), and mean 
chemosis (0.20 ± 0.08, P = 0.017) were also all significantly greater in CAE-treated subjects. 
Confocal microscopic images of conjunctival vessels after CAC showed more inflammation in 
CAE-treated subjects.
Conclusion: In subjects with both dry eye and allergic conjunctivitis, exposure to adverse 
environmental conditions causes an ocular surface perturbation that can intensify allergic 
reactions.
Keywords: allergic conjunctivitis, dry eye, conjunctival allergen challenge, controlled adverse 
environment, comorbidity
Introduction
Allergy is described as the fifth leading group of chronic diseases, affecting 50 million 
Americans. The Third National Health and Nutrition Examination Survey recently 
reported that 40% of the population had episodes of ocular allergy.1 Dry eye disease 
has a prevalence estimated at 5%–30% of the general population, with variations 
according to age and gender.2 In a survey by the American Academy of Ophthalmology, 
respondents reported that approximately 30% of patients seeking treatment at an 
ophthalmologist’s office have symptoms consistent with dry eye disease.3 It has been 
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estimated that in the US, approximately 5 million people 
50 years and older have moderate to severe dry eye.4
The magnitudes of these reported incidences of allergic 
conjunctivitis and dry eye disease suggest that there 
could be significant comorbidity.5,6 The variable nature 
of dry eye pathophysiology has in large part prevented 
epidemiological studies on its coexistence in patients with 
allergic conjunctivitis. Dry eye and allergic conjunctivitis 
share signs and symptoms, complicating a differential 
diagnosis.5,6 Inflammation is a key feature in dry eye,7 and 
is known to be an important component of chronic ocular 
allergy.8–11 The tear film insufficiency and ocular surface 
inflammation present in dry eye disease might be expected to 
facilitate allergen entry and exacerbate allergic ocular signs 
and symptoms in a sensitized individual, but no studies have 
yet shown this association.
The objective of the current study was to determine 
whether subjects with a history of both dry eye and ocular 
allergy would show a heightened reaction to an allergen 
challenge following an adverse environmental exposure.
Materials and methods
Study design
This study was conducted in accordance with institutional 
review board (Alpha IRB, San Clemente CA) regulations and 
with the ethical principles that originated with the Declaration 
of Helsinki. Written informed consent was obtained from 
each subject prior to any study procedures.
Subject inclusion and exclusion criteria
Subjects were $18 years of age and had to have a diagnostic 
skin test indicative of allergy to cat hair or dander, grasses, 
ragweed, dust mites, dog dander, cockroach, or tree antigens, 
as well as a history of seasonal or perennial allergic 
conjunctivitis for at least one year prior to visit 1. Subjects 
also had to have a diagnosis of dry eye and a history of use 
or a desire to use tear substitutes in the previous 6 months, 
as well as a total corneal fluorescein staining score of $2 on 
a predefined Ora CalibraTM scale from 0 to 4, with 0 = none 
and 4 = worst in at least one eye at visit 1. All subjects had to 
have a best corrected visual acuity of +0.7 or better assessed 
by the Early Treatment of Diabetic Retinopathy Study scale 
in both eyes at visit 1.
Subjects were excluded if they had: any significant 
ocular infection or inflammation other than dry eye; ocular 
surgery within 3 months prior to visit 1 or refractive surgery 
within 6 months; any history of retinal detachment, diabetic 
retinopathy, or progressive retinal disease; or any history of 
anaphylactic reaction to any allergens used in this study or 
any systemic disease or uncontrolled medical condition that 
in the opinion of the investigator could have interfered with 
the study. Contact lens wear was prohibited up to 7 days 
prior to visit 1, as well as use of the following medications 
(washout period prior to visit 1 in parentheses): systemic or 
ocular H1 antihistamines or H1 antihistamine-vasoconstrictor 
drug combinations (72 hours); decongestants, monoamine 
oxidase inhibitors, artificial tears, or lid scrubs, mast cell 
stabilizers, prostaglandins or prostaglandin derivatives, and 
ocular, topical or systemic nonsteroidal anti-inflammatory 
drugs (7 days); inhaled, ocular, or topical corticosteroids 
(14 days), depot corticosteroids (45 days), all other topical 
ophthalmic preparations (72 hours), and lastly, no change 
in immunotherapy for at least 2 months prior to and during 
the study. Subjects could have withdrawn from the study at 
any time, and the investigator could have discontinued any 
subject at any time for safety reasons.
The conjunctival allergen challenge (CAC) model12,13 
was used to select subjects who had a reproducible and 
predefined response to the allergen challenge. Those subjects 
who responded positively to CAC must also have reported a 
history of dry eye. Eligible subjects were then randomized 
into two groups in a masked fashion. Prior to CAC, half 
of the subjects (group A, CAE + CAC), were exposed for 
90 minutes to a controlled adverse environment (CAESM) 
chamber,14–16 a dry eye research model that exacerbates signs 
and symptoms of dry eye in a controlled manner by regulating 
humidity, temperature, airflow, lighting conditions, and 
visual tasking. The second half of the subjects (group B, CAC 
only) waited for 90 minutes in a normal environment and had 
signs and symptoms of dry eye assessed in a manner identical 
to group A. Both groups then received the CAC 30 minutes 
after completion of the CAE exposure. The magnitude of the 
allergic responses was compared.
The study comprised three visits over a 6-day period:
•	 visit 1 (day 0) screening, allergen titration
•	 visit 2 (day 3) allergen confirmation CAC, enrollment, 
randomization
•	 visit 3 (day 6) CAE exposure followed by repeat CAC 
(Figure 1).
Efficacy and safety measures
Subject assessment of ocular itching employed the Ora Calibra 
itch scale, a 0–4 scale where 0 = none and 4 = incapacitating. 
Subjects also graded tearing, eyelid swelling, ocular 
discomfort, a four-symptom questionnaire, and nasal signs 
and symptoms using 0–4 scales. The investigator graded 
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ocular redness using the Ora Calibra redness scale 
(conjunctival, episcleral, ciliary; 0 = none to 4 = extremely 
severe) and chemosis at 7, 15, and 20 minutes post-CAC 
(0–4 scale). Safety parameters were pregnancy testing, 
slit lamp biomicroscopy, visual acuity, and adverse event 
reporting.
Exploratory measures
Confocal microscopy (Heidelberg Retinal Tomography II, 
Heidelberg Engineering, Carlsbad, CA) was used to visualize 
superficial conjunctival blood vessels as an indicator of the 
allergic reaction. Images were obtained at visit 1 (baseline) 
and post-CAC at visits 2 and 3. The images were evaluated 
using the Ora Calibra conjunctival inflammation confocal 
scale (patent pending), a 0–4 scale to grade for leukocyte 
presence and adhesion in and around the conjunctival blood 
vessels.
Screening and allergen titration
At visit 1, demographic data and medical histories were 
recorded and medication washout periods were determined 
to be adequate. A urine pregnancy test was given to women 
of childbearing potential. The following procedures were 
carried out: best corrected visual acuity (eligible subjects had 
a logMAR score of 0.70 or better in each eye), subjective 
ocular discomfort score and four-symptom questionnaire, 
ocular and nasal allergic signs and symptoms, slit-lamp 
biomicroscopy, tear film break-up time (TFBUT), fluorescein 
corneal staining, and baseline confocal biomicroscopy.
Twenty minutes after baseline confocal microscopy, the 
titration CAC was carried out bilaterally with one allergen 
to which the subject was sensitized (cat dander, dog dander, 
cockroach, dust mite, meadow fescue, Kentucky bluegrass, 
ragweed, or timothy grass). One drop of solubilized allergen 
at the weakest dilution was instilled bilaterally into the 
20-min wait after 
fluorescein staining
Post-CAE or WAIT 
signs and symptoms
90-minute CAE or 
WAIT period with 
ODS graded every 
5 mins
CAE or WAIT
Microscopy
CAC Confocal
30-minute waiting 
period for all 
subjects
Post-CAC signs and 
symptoms CAC all 
subjects
Confocal
microscopy
+ 1-hr post-CAC
Confocal
microscopy at 
+ 2-hr post-CAC
Confocal
microscopy at 
+ 3-hr post-CAC
Confocal
microscopy at 
+ 4-hr post-CAC
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Figure 1 Study visit 3 diagram.
ABC
Figure 2 Representative frames from confocal video-microscopy of the bulbar conjunctiva. (A) Image captured prior to treatments. note that longitudinal vessels contain 
translucent redness cells, and no white cells are visible. (B) Image captured one hour following allergen challenge; white cells are visible within the vasculature; several appear 
to be either adhering to vessel wall or in process of diapedesis. (C) Image captured one hour following allergen challenge in subject exposed to CAE (90 minutes) prior to 
challenge. 
Note: White cells are visible in the vasculature and white cell infiltration into tissues surrounding vessels is extensive.
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conjunctival cul de sac. If the subject failed to react within 
ten minutes, increasingly concentrated doses were instilled 
bilaterally at 10-minute intervals until a positive reaction 
was elicited. If a positive reaction was not elicited with the 
first allergen, other allergens to which the subject’s skin test 
was positive could have been used. A positive CAC reaction 
was defined as a score of $2 for ocular itching and $2 
for conjunctival redness in both eyes within 10 minutes of 
receiving that dose of allergen. Any subject who failed to 
test positively was excluded from the study. Post-CAC ocular 
and nasal signs and symptoms were assessed. Any subject 
who experienced discomfort from the allergic reaction was 
given a commercially available antiallergy relief medication 
(Visine-A®) after the ocular allergy endpoints were assessed 
and before exiting the clinic.
Allergen confirmation
At visit 2, medical and medication histories were updated 
and subjects were asked if any adverse event had occurred 
after visit 1. Best corrected visual acuity, ocular discomfort, 
four-symptom questionnaire (Ora Calibra four-symptom 
assessment questionnaire grading burning, dryness, grittiness, 
stinging on a 0–5 scale where 0 = none and 5 = worst), ocular 
and nasal allergic signs and symptoms, slit lamp biomicroscopy, 
TFBUT, and corneal fluorescein staining were carried out.
At least 15 minutes after fluorescein staining, the CAC 
was then repeated bilaterally using the same dose of allergen 
that elicited a positive response at visit 1. Subjects assessed 
ocular itching at 3, 5, and 7 minutes post-CAC and graded 
tearing, eyelid swelling, and nasal signs and symptoms 
at 7, 15, and 20 minutes post-CAC. The investigator graded 
ocular redness (conjunctival, episcleral, ciliary) and chemosis 
at 7, 15, and 20 minutes post-CAC. Subjects had to react with 
a $2 in itching and redness at two of these three corresponding 
post-CAC time points to be eligible to continue in the study.
Eligible subjects were randomized into two groups: 
group A, to undergo the 90-minute CAE challenge at visit 
3 (day 6) prior to a repeat CAC and group B, to wait in a 
normal environment for the same 90-minute period prior to 
a repeat CAC. Subjects were further randomized into five 
subgroups for confocal microscopy at 1, 2, 3, 4, and 5 hours 
post-CAC at visits 2 and 3. After confocal microscopy, relief 
medication was provided if necessary.
CAE followed by conjunctival allergen 
challenge
At visit 3, medical and medication histories were updated 
and subjects were asked if any adverse event had occurred 
after visit 2. BCVA, ocular discomfort, four-symptom 
questionnaire, ocular and nasal allergic signs and symptoms, 
slit-lamp biomicroscopy, TFBUT, and corneal fluorescein 
staining were carried out.
Twenty (±5) minutes after fluorescein staining, group A 
subjects underwent the 90-minute CAE exposure. Both groups 
graded ocular discomfort at time 0 and every 5 minutes 
(±one minute) thereafter for 90 minutes. Post-CAE, slit 
lamp biomicroscopy, TFBUT, and fluorescein staining were 
performed.
Within 30 minutes of exiting the CAE, a CAC was 
administered to both groups at the same allergen dose that 
elicited a positive reaction at visit 2. Post-CAC ocular and 
nasal signs and symptoms were assessed. Subjects then 
waited their specified time (1, 2, 3, 4, or 5 hours post-
CAC), before undergoing confocal microscopy. Adverse 
events were assessed and relief medication provided at 
the subject’s request. Subjects were then exited from the 
study.
Statistical methods
The primary efficacy variables were ocular itching 
evaluated by the subject at 3, 5, and 7 minutes post-CAC 
and conjunctival redness evaluated by the investigator at 
7, 15, and 20 minutes post-CAC at visit 3. The secondary 
efficacy variables were ciliary and episcleral redness 
and chemosis graded by the investigator at 7, 15, and 
20 minutes post-CAC and eyelid swelling, tearing, and 
nasal signs and symptoms evaluated by the subject at 7, 
15, and 20 minutes, as well as inferior corneal fluorescein 
staining at visit 3. Mean scores at all time points post-CAC 
were also calculated, as well as mean scores in all three 
redness regions.
Continuous variables were summarized using descriptive 
statistics, including means, medians, standard deviations, 
minimums, and maximums. Categorical variables were 
summarized with frequencies and percentages. Statistical 
analyses were performed with SAS version 9.2 (SAS Institute 
Inc, Cary, NC).
It was hypothesized that eyes would have shown an 
increase in post-CAC ocular itching and/or conjunctival 
redness at any post-CAC assessment after having been 
exposed to the CAE for 90 minutes. This hypothesis was 
assessed by comparing mean scores for groups A and B. 
The 17 with allergic conjunctivitis subjects and dry eye 
gave a power of 75% to detect, at the 5% level, a group 
difference of 0.75 units in mean ocular itching or mean 
conjunctival redness. This calculation assumed that the 
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common standard deviation of scores averaged over the 
eyes was 0.75.
The primary and secondary efficacy parameters were 
analyzed by a repeated-measurement normal linear model 
estimated by generalized estimating equation methods. 
Wald tests based on this model were two-sided and used 
significance levels of 5%. Estimates, tests, and confidence 
intervals were made with and without adjustment for visit 
2 baseline scores.
Confocal microscopy profiles were estimated as a 
function of time from exiting the CAC. For broad statistical 
comparisons, the mean of the inflammation scores over the 
5-hour period was calculated and the two groups, with and 
without CAE pretreatment, were compared.
Results
Demographic data
Thirty-three subjects were screened on visit 1. Of these, 11 
failed to meet all inclusion and exclusion criteria. Twenty-two 
subjects returned for visit 2 and five of these failed to have a 
sufficient CAC response and were thus eliminated from the 
study. The final numbers of subjects who completed the study 
were nine in group A (CAE + CAC) and eight in group B 
(CAC only).
Group A had a mean age of 55.22 ± 12.01 years, with 
a range from 26 to 68 and a median of 58 years. Group B 
had a mean age of 63.50 ± 7.73 years, with a range from 56 
to 75 and a median of 61 years. These differences were not 
statistically significant (P = 0.096). Group A was comprised 
of four males and five females and group B of five males 
and three females. All subjects were Caucasian. No protocol 
deviations or adverse events occurred during the study.
Effects of CAE on dry eye signs  
and symptoms
Table 1 provides data that confirmed the effects of the CAE 
challenge on dry eye/allergic subjects (group A) compared 
with similar subjects who waited the 90-minute period in 
a normal environment (group B). After a CAE challenge, 
mean (±standard error) superior fluorescein staining scores 
were 1.92 ± 0.30 for group A and 1.38 ± 0.28 for group B. 
After adjustment for baseline, this 0.68 ± 0.29 difference 
was statistically significant (P = 0.019). The total mean 
fluorescein staining score was almost significantly different 
between groups, at 1.47 ± 0.25 for group A versus 1.13 ± 0.23 
for group B, with an adjusted for baseline mean difference 
of 0.53 ± 0.27 (P = 0.052).
These staining differences were also reflected in 
differences in ocular discomfort scores. After a 90-minute 
CAE, mean ocular discomfort scores were 3.50 ± 0.17 for 
group A and 1.31 ± 0.55 for group B, representing a mean 
difference of 2.19 ± 0.55 (P , 0.001). After adjustment 
for baseline, this mean difference of 2.11 ± 0.60 was still 
significant (P , 0.001). This was also the case for mean 
ocular discomfort scores graded during the CAE every 
5 minutes from 5 to 90 minutes (a mean of 18 assessments). 
Without adjustment for baseline, mean overall discomfort 
was 3.01 ± 0.20 for group A and 1.24 ± 0.36 for group B, 
a highly significant difference of +1.77 ± 0.40 (P , 0.001). 
After adjustment for baseline, the mean difference was 
still significant at 1.58 ± 0.41 (P , 0.001). These results 
confirmed the effects of a 90-minute CAE challenge on the 
signs and symptoms of dry eye in a population of dry eye/
allergic subjects. There was no significant difference in 
TFBUT between these two groups, ie, the CAE did not have 
Table 1 Effects of a CAE challenge in predefined subjects with a history of dry eye and allergic conjunctivitis (group A, CAE + CAC) 
compared with similar subjects who remained for the 90-minute challenge period in a normal environment (group B, CAC only) 
Sign or symptom of dry eye Group A  
CAE
Group B  
No CAE 
Mean difference  
unadjusted for  
baseline ± SE
P value Mean difference  
adjusted for  
baseline ± SE
P value
Mean ± SE   
(n = 9)
Mean ± SE   
(n = 8)
Central fluorescein staining 0.61 ± 0.23 0.41 ± 0.20 0.20 ± 0.31 0.505 0.32 ± 0.33 0.336
Inferior fluorescein staining 1.89 ± 0.29 1.59 ± 0.28 0.30 ± 0.40 0.465 0.34 ± 0.29 0.242
Superior fluorescein staining 1.92 ± 0.30 1.38 ± 0.28 0.54 ± 0.41 0.190 0.68 ± 0.29 0.019
Mean fluorescein staining 1.47 ± 0.25 1.13 ± 0.23 0.35 ± 0.34 0.313 0.53 ± 0.27 0.052
Ocular discomfort scores at 90 minutes  
post-CAE
3.50 ± 0.17 1.31 ± 0.55 2.19 ± 0.55 ,0.001 2.11 ± 0.60 ,0.001
Ocular discomfort scores during CAE  
(mean of 18 scores from 5–90 minutes)
3.01 ± 0.20 1.24 ± 0.36 1.77 ± 0.40 ,0.001 1.58 ± 0.41 ,0.001
TFBUT 2.83 ± 0.39 2.89 ± 0.30 -0.06 ± 0.50 0.904 0.09 ± 0.47 0.855
Note: These results confirmed the exacerbating effect of CAE on dry eye signs and symptoms.
Abbreviations: CAE, controlled adverse environment; CAC, conjunctival allergen challenge; SE, standard error of the mean; TFBUT, tear film break-up time.
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Table 2
Sign/symptom/ 
time post-CAC
Visit 2 (day 3)a (baseline CAC) Visit 3 (day 6) (±CAE exposure 30 minutes prior to CAC)
Group A  
sample mean   
± SE (n = 9)
Group B  
sample mean  
± SE (n = 8)
Group A  
(CAE) adjusted from  
baseline model means
Group B  
(no CAE) adjusted 
from baseline model 
means
Mean  
difference   
± SEb
95% CI P valuec
Ocular itching
Pre-CAC 0.50 ± 0.21 0.72 ± 0.35 0.39 0.06 0.33 ± 0.15 0.04–0.62 0.024
3 minutes 2.42 ± 0.32 2.31 ± 0.22 1.97 2.29 -0.32 ± 
0.42
-1.15–0.50 0.444
5 minutes 2.89 ± 0.29 2.47 ± 0.21 2.64 2.62 0.02 ± 0.39 -0.74–0.77 0.968
7 minutes 2.89 ± 0.29 2.56 ± 0.22 3.15 2.61 0.55 ± 0.25 0.06–1.03 0.028
Average of 3, 5, 7 
minutes
2.73 ± 0.28 2.45 ± 0.21 2.59 2.50 0.08 ± 0.33 -0.57–0.73 0.801
Conjunctival 
redness
Pre-CAC 0.86 ± 0.26 0.50 ± 0.09 0.81 0.62 0.19 ± 0.35 -0.51–0.88 0.596
7 minutes 1.78 ± 0.13 2.19 ± 0.14 1.89 1.31 0.59 ± 0.19 0.21–0.96 0.002
15 minutes 2.06 ± 0.15 2.53 ± 0.12 2.00 1.75 0.25 ± 0.14 -0.02–0.52 0.066
20 minutes 2.22 ± 0.11 2.78 ± 0.14 2.00 1.71 0.29 ± 0.24 -0.18–0.76 0.222
Average of 7, 15, 
20 minutes
2.02 ± 0.12 2.50 ± 0.12 1.99 1.56 0.43 ± 0.17 0.10–0.77 0.012
Notes: aVisit 2 was a baseline CAC, no CAE was performed, and therefore no statistical modeling between the two groups was done. Sample means and standard errors 
are reported; bmean ± standard error differences were calculated by subtracting group B scores from group A scores; this mean difference between the groups was the 
outcome of interest; cP values from a repeated measurement normal linear model with adjustment for visit 2 baseline. 
Abbreviations: CAE, controlled adverse environment; CAC, conjunctival allergen challenge; CI, confidence interval; SE, standard error of the mean.
an adverse effect on TFBUT in this study. Mean TFBUT 
was 2.83 ± 0.39 in group A and 2.89 ± 0.30 in group B, 
representing a nonsignificant difference of -0.06 (P = 0.904). 
After adjustment for baseline, this mean difference was still 
not significant (0.09 ± 0.47, P = 0.855).
Effects of CAE on conjunctival allergen 
challenge response
Primary endpoints
Significant differences between group A (CAE + CAC) and 
group B (CAC only) were noted in the primary endpoints 
of ocular itching and conjunctival redness post-CAC. 
Table 2 shows the ocular itching and conjunctival redness 
data for the visit 2 baseline CAC and visit 3 (CAC ± CAE) 
assessments. At baseline, pre-CAC, ocular itching was 
significantly greater in CAE-exposed subjects (mean 
difference between groups, 0.33 ± 0.15, P = 0.024). At 
7 minutes after CAC, both ocular itching (mean difference 
between groups, 0.55 ± 0.25, P = 0.028) and conjunctival 
redness (mean difference between groups, 0.59 ± 0.19, 
P = 0.002) were greater in CAE-exposed subjects. The overall 
mean post-CAC conjunctival redness score (mean of the 7, 
15, and 20 minutes post-CAC scores) was also significantly 
higher in CAE-exposed subjects (mean difference between 
groups, 0.43 ± 0.17, P = 0.012).
Secondary endpoints
Increased redness was observed in the secondary endpoints 
in the CAE-exposed subjects (see Table 3). At 7 minutes 
after CAC, both episcleral redness (mean difference between 
groups, 0.56 ± 0.19, P = 0.003) and mean redness in all 
regions (conjunctival, ciliary, episcleral; mean difference 
between groups, 0.59 ± 0.14, P , 0.001) were greater in 
CAE-exposed subjects. The mean post-CAC episcleral redness 
score (mean of the 7, 15, and 20 minute post-CAC scores) 
was also significantly greater in CAE-exposed subjects (mean 
difference between groups, 0.49 ± 0.15, P = 0.001). There were 
no increases observed in ciliary redness. The mean post-CAC 
chemosis score (mean of the 7, 15, and 20 minutes post-CAC 
scores) was also significantly greater in CAE-exposed subjects 
(mean difference between groups 0.20 ± 0.08, P = 0.017). 
None of the subject-graded nasal symptom (rhinorrhea, nasal 
pruritus, nasal congestion, ear and palate pruritus) scores were 
significantly different between the two groups.
Exploratory endpoint: confocal microscopy
The visit 1 baseline HRT II confocal microscopy scores 
represent conjunctival vessels in a quiescent state before any 
CAE or CAC challenges. Confocal microscopic evaluation 
of conjunctival vessels revealed post-CAC inflammatory 
changes compared with baseline.
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The visit 1 mean inflammation score for all subjects at 
baseline was 1.24 ± 0.24 (n = 17). The visit 2 post-CAC mean 
inflammation score for all subjects was 2.53 ± 0.17 at the 
mean time after CAC (3.06 hours, n = 17). The post-CAC 
inflammation scores at visits 2 and 3 tended to be higher at 
one hour post-CAC and to decay over time out to 5 hours. 
The numbers of subjects at each of the five hourly post-CAC 
time points at visits 2 and 3 were small (n = 1 or 2), therefore 
a mean value was calculated for the inflammation score at the 
mean time post-CAC. At visit 3, differences in inflammation 
scores between group A and group B were significantly 
different. The mean inflammation scores over the five-hour 
period were 3.16 in group A (n = 6), and 2.51 in group B 
(n = 4), for a group difference of 0.65 ± 0.30, P = 0.031. 
Figure 1 shows confocal microscopic images at baseline 
(1A), CAC only (1B), and CAC-CAE (1C) at approximately 
250 × magnification. More inflammatory cells are evident in 
the subjects from group A who underwent the CAE exposure 
prior to the CAC.
Discussion
The results of this study demonstrate that in subjects with 
a history of both dry eye and ocular allergy, a break in the 
ocular surface has a direct effect on clinical reactions to 
allergens. When the corneal epithelium was compromised by 
a CAE challenge, subjects reacted not only with more severe 
itching, conjunctival and episcleral redness, and chemosis, 
but also with a more rapid response, showing peak redness 
and swelling at 7 minutes following CAC instead of the usual 
peak at 20 minutes. This rapid dilation might reflect a more 
vulnerable conjunctival blood vessel, a pathological state 
brought on by the coexistence of allergy and dry eye, and 
the many inter-related and cumulative events at the origin 
of both diseases.
Epithelial changes in the conjunctiva and its vasculature are 
thought to be intrinsic to allergic disease. In clinical biopsies 
from patients with out-of-season allergic conjunctivitis, 
altered structural and tight junction proteins were found 
in the quiescent conjunctival epithelium.17 Supporting this 
premise, a previous study we conducted in an animal model 
demonstrated that during the late phase of ocular allergy, 
expression of the proteins, ZO1 and E-cadherin, which 
maintain tight junctions between vascular epithelial cells, 
thereby preventing leakage, chemotaxis, and eventual cellular 
infiltration, were decreased significantly.18 This slackening 
of vessels might be accelerated by a dry eye challenge in 
susceptible subjects. Allergen challenge in humans has 
recently been shown to increase hyperemic neuromediators, 
such as substance P and VIP,19 and immunoreactive nerve 
terminals to VIP have been shown to be increased in 
Sjogren’s syndrome.20
In the cytokine-rich environment of the ocular surface in 
dry eye, mast cells in the conjunctival epithelium appear to be 
hyperactivated. The corneal and conjunctival inflammation 
observed in this study after CAE might also have primed 
limbal mast cells, known to be abundant in the eye.21 
A compromised ocular surface might allow more antigen 
to make contact with and bind to mast cells, resulting in a 
heightened allergic response, ie, a lower threshold response, 
in comparison with what occurred in these same subjects with 
a healthy ocular surface the week before. In eyes that had 
undergone the stress of the CAE challenge, which was shown 
before the CAC to have increased discomfort and fluorescein 
staining compared with subjects in a normal environment, 
inflammatory pathways were already activated by neurogenic 
input from the compromised corneal surface, resulting in 
a more rapid and cumulative conjunctival inflammatory 
response to allergen-induced mast cell degranulation. 
Supporting this ripple-down effect from the cornea to the 
conjunctiva, environmental desiccation stress in mice was 
shown to induce T cell-mediated inflammation of the cornea, 
conjunctiva, and lacrimal gland, suggesting that desiccation 
stress exposes shared epitopes in the these tissues.22 While 
preliminary in nature, the evidence provided by confocal 
microscopy does appear to corroborate a background of 
heightened inflammation in the CAE-challenged allergic 
subjects. These trends will be further delineated in future 
studies with a greater number of subjects.
The lack of an effect of CAE on TFBUT was not 
unexpected, because this parameter often appears to be 
independent of positive fluorescein staining, ie, the endpoint 
used in this study as clinical evidence of breaks in the ocular 
surface. Different subsets of dry eye exist,23,24 and it is 
possible that subjects with positive fluorescein staining as 
opposed to altered TFBUT were preselected since staining 
was an entrance inclusion criterion. It is also possible that 
under the desiccating conditions of CAE, reflex tearing 
might have occurred, albeit not therapeutically sufficient 
to diminish the observed corneal staining or the subsequent 
effect on the allergic response.
While the occasional patient may pose a diagnostic 
dilemma, dry eye and allergy are readily separated by 
signs and symptoms. The allergic eye has a moist, mildly 
pinkish-red, microchemotic glaze, and pathognomonic itch, 
while the dry eye has characteristic staining and redness 
predominantly in the horizontal vessels of the interpalpebral 
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fissure. The patient with dry eye will complain of dryness, 
burning, and grittiness particularly in relation to visual 
tasking, and with a notable diurnal component,25 while 
symptoms of the allergic patient are independent of visual 
tasking.
In conclusion, in patients with both ocular allergy and 
dry eye, exposure to an adverse ocular environment prior 
to allergen challenge exacerbated the clinical response of 
itching, redness, and chemosis. This finding might have 
relevance to both the treatment and diagnosis of patients 
with these two diseases. It is not known if the exacerbation 
was due to a breakdown in the tear film barrier leading to 
higher allergen load of mast cells. Future studies are planned 
to identify the comorbidity of allergic conjunctivitis and 
dry eye in our study populations, to delineate further the 
conjunctival vessel changes after CAC through confocal 
microscopy, to identify if an adverse environment challenge 
would exacerbate ocular allergic signs and symptoms in 
normal subjects without dry eye, and to modulate endpoints 
of this dual challenge model with potential treatments for 
ocular allergy and/or dry eye.
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